ADHD Online Unveils a New Corporate Structure, Announces Series AA Investment, Establishes a New Board, and Appoints New CEO
Restructuring enhances operations of the leader in online ADHD assessment and diagnosis and positions the company for growth.
…
ADHD Online Unveils a New Corporate Structure, Announces Series AA Investment, Establishes a New Board, and Appoints New CEO
Restructuring enhances operations of the leader in online ADHD assessment and diagnosis and positions the company for growth.
…
PUNTA SANTOS Debuts as the First-Ever Low-Proof Premium Tequila

Made With 100% Blue Agave and Engineered at 28% ABV, PUNTA SANTOS Blazes New Path in the Spirits Industry
PUNTA SANTOS PUNTA SANTOS Tequila Lique…
The post PUNTA SANTOS Debuts as the First-Ever Low-Proof Premium Tequila first appeared on RSVTV news.
Seattle Stealth Startup Changefly Launches Kickstarter Campaign: Simplifying Accounts and Privacy With Innovative All-in-One App

Cross-Platform, End-to-End Encrypted, All-in-One App Simplifies Accounts, Regains Privacy and Outsmarts Threats
Changefly Simplifies Accounts, Re…
The post Seattle Stealth Startup Changefly Launches Kickstarter Campaign: Simplifying Accounts and Privacy With Innovative All-in-One App first appeared on RSVTV news.
First Stop Health Honored as Winner of the 2023 Well-Being Trailblazer Award
Virtual care company’s commitment to providing high-quality, delightful healthcare experiences is evolving workplace well-being.
CHICAGO, July 20, 2023 (Newswire.com)
–
First Stop Health (FSH), a leading virtual care company for primary, urgent and mental health care needs, is proud to announce its recognition as a winner of the esteemed 2023 Well-Being Trailblazer Award. Presented by Archetype and the Wellness Council of America (WELCOA), this prestigious award celebrates FSH’s contributions to the well-being industry and its commitment to transforming workplace wellness.
“When we provide new services, we do so for the betterment of our users – employees and their family members across the country. That desire is what drove our decision to launch Virtual Primary Care in 2022,” said FSH CEO, Teira Gunlock. “We are excited to be considered a Trailblazer for our approach in delivering convenient, compassionate care.”
“These remarkable companies are leading the way in transforming the well-being landscape, and we have full confidence that they will continue to drive positive change in the sphere of workplace well-being,” commented Iain Fitzpatrick, Chief Strategy Officer at Archetype. “Their innovative approaches and unwavering commitment to improving employee well-being are shaping the future of the industry.”
Presented by Archetype and the Wellness Council of America (WELCOA), the Well-Being Trailblazer Awards celebrate innovative companies reshaping workplace wellness. These prestigious awards recognize organizations enhancing employee well-being, promoting resilience, and setting new standards for well-being technology, products, and services.
FSH is proud to provide care that people love® and its +94 Virtual Primary Care Net Promoter Score (NPS) reflects its commitment to members’ well-being. FSH virtual care is designed to promote equitable, culturally competent and quality-assured healthcare to support the unique needs of patients.
About First Stop Health
First Stop Health (FSH) provides care that people love with various digital healthcare services. Patients can access virtual care 24/7 via app, website or phone. We help them save time and money with safe, convenient, high-quality virtual care solutions – Primary Care, Urgent Care & Mental Health. FSH was named one of Inc. Magazine’s Best Workplaces of 2022 and 2023, and ranked one of the fastest-growing private companies for the past five years by Inc. 5000. FSH was also recognized in Crain’s Chicago Business Fast 50 and ranked one of the Chicago area’s fastest-growing companies.
Contact Information:
Emily Kunisch
Senior Manager, Marketing
888-691-7867 x-410
Original Source:
First Stop Health Honored as Winner of the 2023 Well-Being Trailblazer Award
ISSA, LLC Selected as an Arizona Top Workplace for 2023

Employee-Driven Feedback Secures ISSA This Prestigious Honor
ISSA TEAM MEMBERS ISSA TEAM MEMBERS
PHOENIX, July 20…
The post ISSA, LLC Selected as an Arizona Top Workplace for 2023 first appeared on RSVTV news.
Dr. Eric Grigsby Collaborates on Groundbreaking Study of Donanemab’s Impact on Alzheimer’s Disease
Neurovations Research proud to be a part of study that released first positive results to slow Alzheimer’s Disease
NAPA, Calif., July 19, 2023 (Newswire.com)
–
Neurovations, a leading medical research and innovation company, is proud to have collaborated on a groundbreaking study investigating the effects of the monoclonal antibody, donanemab, on patients with the early stages of Alzheimer’s Disease.
Neurovations began enrolling patients in 2021 in advance of Eli Lilly’s recent announcement of positive results from the TRAILBLAZER-ALZ 2 Phase 3 trial. This study demonstrated that donanemab significantly slowed cognitive and functional decline in individuals with early Alzheimer’s Disease.
“We are thrilled to be part of this vital research. Alzheimer’s Disease affects nearly 1 million people in my home state of California,” said Dr. Eric Grigsby. “This is a significant step forward in the fight against Alzheimer’s, and we are optimistic about the impact this treatment may have on the members of my community with this condition.”
Neurovations was founded in Napa in 1992 by Dr. Eric Grigsby and is a national leader in clinical research for pain and neurologic diseases, treatment for chronic pain, molecular diagnostics testing, and education programs focused on pain and neuroscience.
The TRAILBLAZER-ALZ 2 study, a randomized, double-blind, placebo-controlled trial, evaluated the safety and efficacy of donanemab, an investigational, amyloid-targeting therapy. Participants with early symptomatic Alzheimer’s disease were enrolled in the study, and those with confirmed presence of AD neuropathology completed their course of treatment with donanemab.
Neurovations Research was selected as a study site in 2021 and worked with Eli Lilly to contribute to this groundbreaking research. Dr. Grigsby’s expertise and passion for advancing treatments for neurodegenerative diseases and chronic pain have been instrumental in the success of this collaboration.
Key findings from the TRAILBLAZER-ALZ 2 study include:
● Nearly half (47%) of participants on donanemab showed no clinical progression at one year, defined as no decline in Clinical Dementia Rating-Sum of Boxes (CDR-SB), compared to 29% of participants on placebo.
● Donanemab treatment slowed clinical decline by 35% compared to placebo, leading to a 40% reduction in the decline of activities of daily living.
These results have significant implications for the treatment of early symptomatic Alzheimer’s disease and have prompted Lilly to move forward with FDA approval and global regulatory submissions. Neurovations and Dr. Eric Grigsby’s involvement in this study have further enhanced the research community’s understanding of the potential benefits of donanemab in Alzheimer’s disease management.
“Alzheimer’s Disease affects an estimated 6.7 million Americans aged 65 and older. This first step is monumental on the path to a cure. We are thrilled to have been part of the study and sincerely hope to begin offering the treatment as soon as possible,” stated Dr Grigsby.
Contact Information:
Krista Clark
Marketing Director
7072529665
Original Source:
Dr. Eric Grigsby Collaborates on Groundbreaking Study of Donanemab’s Impact on Alzheimer’s Disease
Dr. Eric Grigsby Collaborates on Groundbreaking Study of Donanemab’s Impact on Alzheimer’s Disease
Neurovations Research proud to be a part of study that released first positive results to slow Alzheimer’s Disease
NAPA, Calif., July 19, 2023 (Newswire.com)
–
Neurovations, a leading medical research and innovation company, is proud to have collaborated on a groundbreaking study investigating the effects of the monoclonal antibody, donanemab, on patients with the early stages of Alzheimer’s Disease.
Neurovations began enrolling patients in 2021 in advance of Eli Lilly’s recent announcement of positive results from the TRAILBLAZER-ALZ 2 Phase 3 trial. This study demonstrated that donanemab significantly slowed cognitive and functional decline in individuals with early Alzheimer’s Disease.
“We are thrilled to be part of this vital research. Alzheimer’s Disease affects nearly 1 million people in my home state of California,” said Dr. Eric Grigsby. “This is a significant step forward in the fight against Alzheimer’s, and we are optimistic about the impact this treatment may have on the members of my community with this condition.”
Neurovations was founded in Napa in 1992 by Dr. Eric Grigsby and is a national leader in clinical research for pain and neurologic diseases, treatment for chronic pain, molecular diagnostics testing, and education programs focused on pain and neuroscience.
The TRAILBLAZER-ALZ 2 study, a randomized, double-blind, placebo-controlled trial, evaluated the safety and efficacy of donanemab, an investigational, amyloid-targeting therapy. Participants with early symptomatic Alzheimer’s disease were enrolled in the study, and those with confirmed presence of AD neuropathology completed their course of treatment with donanemab.
Neurovations Research was selected as a study site in 2021 and worked with Eli Lilly to contribute to this groundbreaking research. Dr. Grigsby’s expertise and passion for advancing treatments for neurodegenerative diseases and chronic pain have been instrumental in the success of this collaboration.
Key findings from the TRAILBLAZER-ALZ 2 study include:
● Nearly half (47%) of participants on donanemab showed no clinical progression at one year, defined as no decline in Clinical Dementia Rating-Sum of Boxes (CDR-SB), compared to 29% of participants on placebo.
● Donanemab treatment slowed clinical decline by 35% compared to placebo, leading to a 40% reduction in the decline of activities of daily living.
These results have significant implications for the treatment of early symptomatic Alzheimer’s disease and have prompted Lilly to move forward with FDA approval and global regulatory submissions. Neurovations and Dr. Eric Grigsby’s involvement in this study have further enhanced the research community’s understanding of the potential benefits of donanemab in Alzheimer’s disease management.
“Alzheimer’s Disease affects an estimated 6.7 million Americans aged 65 and older. This first step is monumental on the path to a cure. We are thrilled to have been part of the study and sincerely hope to begin offering the treatment as soon as possible,” stated Dr Grigsby.
Contact Information:
Krista Clark
Marketing Director
7072529665
Original Source:
Dr. Eric Grigsby Collaborates on Groundbreaking Study of Donanemab’s Impact on Alzheimer’s Disease
Jovive Health Receives LegitScript Certification for Medication-Assisted Treatment Services
Jovive Health is recognized with industry-leading certification for treating patients with opioid use disorder.
EMERYVILL…
Cooper Hues Develops Luxury Technology Platform

Cooper Hues is thrilled to announce a new product addition to the company’s portfolio: Cooper – a global, web-based, luxury services and assets platform
Cooper Logo
Cooper Hues Logo
LOS ANGELES, July 19, 2023 (Newswire.com)
–
The platform is home to a marketplace that hosts listings for luxury asset and service providers, providing customized account access to individual clients, concierge companies and corporate travel groups.
Cooper expands on the company’s proven track record in the luxury industry and is a global expansion for the Cooper Hues product portfolio beyond the private jet charter space. Cooper Hues’ venture into the technology space is aimed at filling a longstanding gap in the industry, whereby, sourcing, booking and reservation management is still a largely manual process. Designed with concierge, vendor and corporate partners in mind, Cooper enables enterprises to instantly increase their global footprint and streamline business operations, saving money and increasing their margins — all while reducing the agency’s overhead that is typically associated with sourcing, quote reviews and reservation management. The platform even includes a commission markup tool and multi-currency, secure payment gateways to make the process of sourcing, customizing and securing a reservation as efficient as possible.
Cooper’s state-of-the-art digital platform also enables independent clients to browse, book and manage their own lifestyle services. The company recognizes modern consumer behavior depicts a change in preferences, with a large majority of industry newcomers looking for more control over their booking experience. Clients have the option of performing one-time reservations or booking assets and services on a recurring subscription basis.
For those requiring more bespoke services, Cooper Hues provides an even higher tier of membership: the Cooper Verified status. Such membership includes ’24/7, 365′ Cooper concierge access with a dedicated Cooper agent. Cooper Verified agents deliver bespoke requests, deals and packages outside of existing marketplace options, and provide client access to ultra-premium categories like private jet club memberships, exclusive parties and more.
“It’s a game changer,” says founder and CEO Gal Ozery. “It does for luxury services what Airbnb did for holiday rentals and what Amazon did to everyday shopping. We combined every asset and service that high-end clients want into a single platform that supports various types of members. Everybody wins.”
Vendors and concierge companies can expect to reduce booking risks, payment delays and lack of data security with the digital storefront and partner services provided by Cooper’s platform. The platform aims to reduce their partners’ overall booking and operations costs by an estimated 10-20% — an overhead cost typically incurred by firms who do not leverage technology to source, quote and manage their client books.
Cooper Hues has already begun accepting new clientele and partners amidst the pre-launch, and is opening the books to more clients, vendors, corporate, and concierge companies ahead of the global launch.
For more information on Cooper, to become a vendor, concierge or corporate member, or to invest in Cooper Hues, go to https://www.cooperhues.com/.
Contact Information:
Esther Adeyemi
CMO
Belinda Brown
PR
19145231267
Original Source:
Cooper Hues Develops Luxury Technology Platform
The post Cooper Hues Develops Luxury Technology Platform first appeared on RSVTV news.
